1 / 3

Amyotrophic Lateral Sclerosis (ALS) Treatment Market New Product Launches, Acquisitions

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron disease (MND), is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord that controls voluntary muscles. <br>

rushi12
Télécharger la présentation

Amyotrophic Lateral Sclerosis (ALS) Treatment Market New Product Launches, Acquisitions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Global Amyotrophic Lateral Sclerosis (ALS) Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market - Size, Share, Growth, Treatment Market - Size, Share, Growth, Outlook, and Opportunity Analysis, 2018-2026 Outlook, and Opportunity Analysis, 2018-2026 Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron disease (MND), is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord that controls voluntary muscles. The disease is progressive in nature, meaning it gets worse over time. Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1206 According to a study published in Centers for Disease Control and Prevention, in 2016, around 14,713 people were diagnosed with ALS in the U.S. and prevalence rate of ALS was 4.7 cases per 100,000 people in 2012. The prevalence rate increased to 5.0 cases per 100,000 people and around 15,908 people were diagnosed with ALS in 2013, according to the same study. The increasing prevalence of ALS is in turn, expected to support growth of the amyotrophic lateral sclerosis (ALS) treatment market in the near future. Approval of novel innovative drugs is expected to boost growth in amyotrophic lateral sclerosis treatment market In May 2017, The U.S. Food and Drug Administration (FDA) approved Radicava (edaravone), an innovative drug used in the treatment of amyotrophic lateral sclerosis (ALS). This was the first drug to be approved after over 20 years since the last FDA-approved drug for ALS. The approval of this drug would provide an additional option for patients suffering from this deadly disease. Increasing incidence of ALS is expected to increase the adoption rate of this drug, in turn, boosting market growth. The drug has already been approved in Japan and South Korea in 2015. Report includes chapters which deeply display the following deliverable about industry :

  2. • Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Research Objective and Assumption • Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Regions • Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Major players operating in the global amyotrophic lateral sclerosis treatment market include Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company Ltd., Sanofi S.A., and Mylan Pharmaceuticals Inc. Inquire Here Before Purchase: https://www.coherentmarketinsights.com/insight/talk-to-analyst/1206 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Taxonomy The global amyotrophic lateral sclerosis treatment market is segmented on the basis of drug type and distribution channel. On the basis of drug type, the global amyotrophic lateral sclerosis treatment market is segmented into:

  3. Riluzole Edaravone (Radicava) • • On the basis of distribution channel, the global amyotrophic lateral sclerosis treatment market is segmented into: Hospital Pharmacies Retail & Online Pharmacies • • About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

More Related